<DOC>
	<DOCNO>NCT01147172</DOCNO>
	<brief_summary>Elevess intend skin type . However , study soft tissue filler need people color increase use cosmetic dermal filler product . This study design evaluate safety injectable hyaluronic acid base dermal filler Elevess ( Anika Therapeutics , Inc. , Bedford , MA ) . Safety evaluate incidence severity keloid formation pigmentation change , potential adverse event people Fitzpatrick skin type IV , V VI elect undergo nasolabial fold ( NLF ) treatment Elevess . 1 . Fitzpatrick Classification Skin Type : IV - Burns minimally , always tan well ( moderate/light brown skin ; Mediterranean , Asian , Hispanic . V - Rarely burn , tan profusely ( dark brown/brown skin : Middle eastern , Latin , light skin Black , Indian ) VI - Never burn , ( deeply pigment dark brown black skin ; Black )</brief_summary>
	<brief_title>Safety Study Cosmetic Tissue Augmentation People Color</brief_title>
	<detailed_description>This study design open-label , longitudinal , uncontrolled study minimum 100 subject Fitzpatrick scale skin type IV , V VI 10 U.S. center elect undergo NLF treatment intradermal ( deep dermal ) injection Elevess . Subjects follow minimum 24 week visit assessment 2 , 6 , 12 24 week last injection . Safety : Primary Safety Endpoint assessment : 1 ) keloid formation site injection 2 , 6 , 12 24 week , 2 ) pigmentation change site injection compare adjacent skin 2 , 6 , 12 24 week , 3 ) overall adverse event . A subject diary also collect . Effectiveness : No formal effectiveness evaluation perform .</detailed_description>
	<criteria>Fitzpatrick skin type IV , V VI . Bilateral nasolabial fold , investigator 's judgment , correct Elevess . Age great equal 18 year . Fitzpatrick skin type I , II III . Subject severe allergy manifest history anaphylaxis history presence multiple severe allergy . Subject allergy component Elevess : hyaluronic acid , lidocaine , sodium metabisulfite gram positive bacterial protein . Subject history severe keloid and/or hypertrophic scar . Subject ever receive soft tissue augmentation area face subject unwilling forgo soft tissue augmentation duration study . Subject receive aesthetic dermatologic treatment procedures area face previous 6 month subject unwilling forgo treatment procedures duration study . Subject active facial acne lesion , severe acne scar pigmentation disorder injection site might affect clinical assessment nasolabial fold . Subject ever receive injection implant silicone area face . Subject receive immunosuppressive therapy , chemotherapy , systemic corticosteriods within last 3 month . Subject history connective tissue disease . Subject positive HIV/AIDS hepatitis C. Subject involve research study involve investigational product ( drug , device biologic ) new application approve product , within 30 day screen</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Nasolabial Folds</keyword>
	<keyword>Cosmetic</keyword>
	<keyword>Injectable Dermal Filler</keyword>
	<keyword>Hyaluronic Acid Lidocaine</keyword>
</DOC>